More Than 'That Old Shkreli Co.,' KaloBios Ready To Innovate, Change Biotech
Executive Summary
KaloBios Pharmaceuticals Inc. is now free of Martin Shkreli, after the pharma 'bad boy' sold his remaining stock, and wants to get on with its work of focusing on R&D of medicines that benefit patients with rare and neglected diseases. But the firm also has some ideas it thinks could change biotech.
You may also be interested in...
Bridging The Drug Price Divide: Ideas And Approaches Debated At PSA
Leaders from across the industry met at Informa's Pharmaceutical Strategy conference and addressed some of the most critical issues facing the industry: pharma's tarnished reputation and drug pricing.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.